(Approval lapsed) Flebogamma 5% DIF Immune Globulin Intravenous (Human) 20gm/400mL (Grifols USA)
Section 19A approved medicine
(Approval lapsed) Flebogamma 5% DIF Immune Globulin Intravenous (Human) 20gm/400mL (Grifols USA)
Section 19A approval holder
Grifols Australia Pty Ltd ABN 35 050 104 875
Phone
03 9535 9333
Approved until
Status
Expired
Medicines in short supply/unavailable
FLEBOGAMMA 5% DIF normal immunoglobulin (Human) 20g/400mL intravenous use injection vial - ARTG 143803
Indication(s)
Replacement therapy in: Primary immunodeficiency syndromes such as:
- congenital agammaglobulinaemia and hypogammaglobulinaemia
- common variable immunodeficiency
- severe combined immunodeficiency
- Wiskott Aldrich syndrome
Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
Children with congenital AIDS and recurrent infections.
Immunomodulation:
- Idiopathic thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.
- Guillain Barré syndrome.
Allogeneic bone marrow transplantation.